DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20191715

Extra medullary multiple myeloma of knees: a case report

Sagar Bhalerao, Aditya Adhav, Rajnish Nagarkar

Abstract


Multiple myeloma is defined as an incurable, complex, and rare malignant disease of the plasma cells. Multiple myeloma is characterized by uninhibited proliferation of clonal plasma cells. Extramedullary disease is characterized by the presence of clonal plasma cell infiltrate adjacent to soft tissues or distant from the bone marrow in patients with underlying MM. Survival of patients with MM is low. A 65-year-old female reports to the outpatient clinics with pain in the left lower limb for over 2 months. The patient had loss of range of motion. True-cut biopsy revealed multiple myeloma of synovial sarcoma. Extramedullary disease is considered as an uncommon manifestation of multiple myeloma. It is either a newly diagnosed disease or evolves with repeated relapses. There is no clear data on the incidence of extramedullary disease. Since there is a no standard treatment for extramedullary disease, its prognosis remains poor.


Keywords


Extra medullary disease, Myeloma, PET-CT, Plasmacytoma, Prognosis, Survival

Full Text:

PDF

References


Eslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013;42(10):684-8.

Mai EK, Haas EM, Lücke S, Löpprich M, Kunz C, Pritsch M, et al. A systematic classification of death causes in multiple myeloma. Blood Cancer J. 2018;8(3):30.

Prideaux SM, Conway O’Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Advances Hematol. 2014:864058.

Al-Farsi K. Multiple myeloma: an update. Oman Medical J. 2013;28(1):3-11.

Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54(6):1135-41.

Bladé J, de Larrea CF, Rosiñol L. Extramedullary involvement in multiple myeloma. Haematologica. 2012;97(11):1618-9.

Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364(1):32-51.

Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:157496.

Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127(8):971-6.

Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematol 2014;99(2):360-4.

Celotto K, Lee K. End-stage Myeloma with Extramedullary Plasmacytomas in the Era of Novel Therapies. AJHO. 2017;13(2):21-3.